Cernilton and BPH

A selection of studies performed in patients with BPH using Cernilton
Author Year Study Titel / Study Design No of patients
Becker et al 1988 Conservative treatment of benign prostatic hyperplasia (BPH) with
Cernilton N - Results of a placebo-controlled double-blind study.
48/48
Buck et al 1990 Treatment of outflow tract obstruction due to benign prostatic hyperplasia with
the pollen extract, Cernilton. A double-blind, placebo-controlled study.
29/24
Maekawa et al 1990 Clinical eveluation of Cernilton on benign prostatic hypertrophy
– A multi center double-blind study with Paraprost
79/80
Braun et al 1993 Double-blind multi-center placebo-controlled study of efficacy and tolerability
of Adenoprostal1 in patients with benign prostatic hyperplasia (BPH)
1) Triple-strength Cernitol
25/19
Dutkiewicz 1996 Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Comparative study vs Tadenan (Pygenum Africanum)
51/38
Aoki et al 2002 Clinical evaluation of the effect of tamsulosin hydrochloride and Cernitin pollen extract on
urinary disturbance associated with benign prostatic hyperplasia in a multicentered study
Cernilton: 73
Tamsulosin: 67
Combination: 72

Cernilton is a registered trademark of AB Cernelle
AB CERNELLE • HÖGANÄSVÄGEN 365 • SE-262 94 ÄNGELHOLM • SWEDEN • TEL +46 (0)42 69 230 • This email address is being protected from spambots. You need JavaScript enabled to view it.WWW.CERNELLE.COMSITEMAP